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Abstract
Peptides originating from different sources (endogenous, food derived, environmental, and synthetic) are able to
influence different aspects of epigenetic regulation. Endogenous short peptides, resulting from proteolytic cleavage
of proteins or upon translation of non-annotated out of frame transcripts, can block DNA methylation and hereby
regulate gene expression. Peptides entering the body by digestion of food-related proteins can modulate DNA
methylation and/or histone acetylation while environmental peptides, synthesized by bacteria, fungi, and marine
sponges, mainly inhibit histone deacetylation. In addition, synthetic peptides that reverse or inhibit different
epigenetic modifications of both histones and the DNA can be developed as well. Next to these DNA and histone
modifications, peptides can also influence the expression of non-coding RNAs such as lncRNAs and the maturation
of miRNAs.
Seen the advantages over small molecules, the development of peptide therapeutics is an interesting approach to
treat diseases with a strong epigenetic basis like cancer and Alzheimer’s disease. To date, only a limited number of
drugs with a proven epigenetic mechanism of action have been approved by the FDA of which two (romidepsin
and nesiritide) are peptides. A large knowledge gap concerning epigenetic effects of peptides is present, and this
class of molecules deserves more attention in the development as epigenetic modulators. In addition, none of the
currently approved peptide drugs are under investigation for their potential effects on epigenetics, hampering drug
repositioning of these peptides to other indications with an epigenetic etiology.
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Background
The term epigenetics was first coined by Conrad Wadding-
ton in 1942 [1]. It refers to all heritable alterations in gene
expression and chromatin structure due to biochemical
modifications that do not change the primary gene nucleo-
tide sequence [2]. These epigenetic tags are passed through
to the offspring by epigenetic modifications in the germline
cells [3]. However, this central dogma of non-genetic inherit-
ance is under pressure as studies also suggest that sperm
cells are epigenetically reprogrammed and reconstructed
after fertilization [4]. The main mechanisms of epigenetics
include DNA methylation, histone post-translational modifi-
cations (hPTMs) and variants, chromatin remodeling, and
non-coding RNAs (ncRNAs). These epigenetic modifications
are influenced by environmental and lifestyle factors such as
diet, the microbiome, physical activity, and pollutants/toxins
[5–7]. Moreover, the different epigenetic mechanisms can
affect one another, adding extra layers of epigenetic regula-
tion [8–10]. For instance, histone methylation can help
directing DNA methylation patterns and DNA methylation
can act as a template for histone modifications [8].
DNA methylations are the most common epigenetic
modifications: a methyl group is transferred from S-
adenosylmethionine (SAM) to the 5′ position of the cyto-
sine ring by a DNA methyltransferase (DNMT) [11]. It is
generally correlated with gene repression by direct block-
ing of transcription factor binding or by recruitment of
chromatin remodeling readers [12, 13]. DNA methylation
plays important roles in genomic imprinting, genome sta-
bility, and suppression of retrotransposons. Abnormal
DNA methylation changes are associated with different
forms of cancer and fragile X syndrome [12, 14, 15]. DNA
methylation is a relatively stable process while demethyla-
tion, which is necessary for gene reprogramming, occurs
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via passive dilution or an active hydroxymethylation
process [16, 17].
Histones associate with DNA to form nucleosome
complexes. Nucleosome compaction of DNA protects
the genome from DNA-damaging agents and allows to
pack all DNA in the nucleus [18]. The best studied his-
tone modifications are acetylation by histone acetyltransfer-
ase (HAT) enzymes and methylation by histone
methyltransferases (HMT). Acetylation neutralizes the posi-
tive charge of lysine on the histones which results in chro-
matin unfolding and gene activation while methylation
exerts its functions indirectly by recruitment of non-
histone proteins of which the outcome (i.e., gene activation
or repression) is dependent on the histone mono-di-tri-
methylation motif, the specific combination of modifica-
tions (histone code) and histone localization along the gen-
etic sequence [19, 20]. The reversed phenomenon is
catalyzed by deacetylases (HDAC) and histone demethy-
lases, respectively. To date, 18 different HDACs are identi-
fied and classified in four different classes. Other
modifications such as butyrylation and succinylation exist
[11]. All these modifications can alter gene expression by
chromatin remodeling, but also play important roles in the
DNA damage response [20]. In addition, canonical histone
proteins can be replaced during cell cycle by non-canonical
histone variants, which are encoded by separate genes.
These variants can change the chromatin properties by de-
stabilizing the nucleosome and altering the hPTM pattern
which can influence gene transcription, DNA replication
and repair, packaging, and segregation [21].
Next to the aforementioned DNA and histone modifiers,
non-coding RNAs (ncRNAs) add another regulatory layer to
the epigenetic machinery. The majority of these RNA mole-
cules do not encode for proteins but can exert a variety of
functions like regulating gene expression and DNA methyla-
tion or chromatin complexes [22–24]. Moreover, its regula-
tory functions are controlled by a plethora of
epitranscriptomic modifications [25–30]. ncRNAs are classi-
fied based on their size: ncRNAs shorter than 200 nucleo-
tides (nt) are called short non-coding RNAs (encompassing
miRNA, siRNA, piRNA), whereas the ones larger than 200
nt are called long non-coding RNAs (lncRNAs) [31, 32]. The
most known and most investigated group of ncRNAs is the
microRNAs (miRNAs). These RNA molecules are about
19–24 nt long and repress gene expression by targeting
mRNA. The miRNA recognizes 6–7 nucleotides in the 5′
untranslated region (“seed” region) of its target and guides
an RNA-induced silencing complex (RISC) to the target
mRNA. When the miRNA is completely complementary
with its target, it acts as an endonuclease and degrades the
mRNA. However, in the majority of the cases, miRNAs are
only partially complementary and inhibit translation by re-
location of the mRNA-miRNA-RISC complex to processing
bodies where mRNA degradation occurs [33]. Since the seed
region is relatively short, one miRNA is able to regulate hun-
dreds of different genes [34]. miRNAs not only target
mRNA, they can also regulate the expression of other
ncRNAs adding an extra layer of epigenetic regulation [35].
To date, more than 1800 putative miRNAs are identified
and collected in the miRBase database [36]. siRNAs have
a similar mechanism of action but differ from miRNA by
source of origin and have subtle structural differences;
miRNA consists of an incomplete hairpin-shaped double-
stranded RNA which is processed by Drosha and Dicer,
whereas siRNA is the product of fully complementary
double-stranded RNA which is only processed by Dicer
[32]. lncRNAs can act as precursors for short ncRNAs or
regulate gene expression at different levels, mainly by
chromatin remodeling [37]. More recently, it has been
found that these lncRNAs can also have, despite their
name, a coding function for small peptides [38, 39].
In this review, we discuss the influence of peptides on dif-
ferent regulatory layers of epigenetics. In addition, we give an
overview of already approved drugs with epigenetic effects
and discuss the potential of therapeutic peptides in this field.
Epigenetics and disease
Dysregulated epigenetics is involved in a wide range of dis-
eases. The reversible nature of epigenetic modifications makes
them interesting therapeutic targets [11]. Epigenetic control
can already be dysfunctional during embryonic development,
possibly caused by increased oxidative stress in sperm cells,
and result in congenital diseases such as fragile X syndrome
and Hirschsprung disease [15, 40–42]. Later in life, adverse
epigenetic regulation can result in a variety of diseases like
cancer [43], blood disorders [44], neurological and neurode-
generative disorders [45–48], and respiratory disorders [49,
50]. These epigenetic shifts can be used as diagnostic markers
in both invasive and non-invasive samples [51–54].
The influence of peptides on epigenetic
mechanisms
Endogenous peptides
Peptides are small proteins buildup of less than 50 amino
acids. These compounds exert a variety of functions in the
human body and are able to modulate epigenetic mecha-
nisms. There are different reports discussing gene regula-
tory effects of peptides [55–58]. Depending on the
peptide, these effects are direct or indirect by binding to
receptors and activation of intracellular signaling cascades
(Table 1). Khavinson et al. discovered a variety of di-, tri-,
and tetra-peptides in the nucleus. These short peptides
directly interact with DNA in the promotor gene region,
causing strand separation and initiation of gene transcrip-
tion. If this is the case, then these short peptides of four
amino acids and less can be considered as a separate class
of epigenetic regulators. Another proposed mechanism of
action is the binding of these peptides to the gene
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promotor region making it inaccessible for DNA methyl-
transferases, resulting in unmethylated promotor regions
and gene activation [59, 60]. This way, the short peptides
act as DNA methylation inhibitors (Fig. 1 (a)). These short
“cryptic” peptides can be formed endogenously by proteo-
lytic cleavage of nuclear proteins or by synthesis after
which they penetrate the cytoplasmic and nuclear mem-
brane [60, 61]. These peptides are involved in the epigen-
etic regulation of aging and can have health-promoting
effects by for example suppressing age-related increased
expression of matrix metalloproteases and caspase-
dependent apoptosis [55, 93].
Amyloid-beta (Aβ), a 37–43-amino acid-long peptide
which is the core component of senile plaques in Alzheimer’s
disease (AD) reduces global DNA methylation but increases
DNA methylation in the promotor region of the neprilysin
gene, an enzyme responsible for Aβ degradation, hence
downregulating its own production [62]. Soluble oligomers
of Aβ are also able to decrease cysteine uptake in human
neuronal cells causing a decrease in intracellular glutathi-
one levels, accompanied by a global decrease in DNA
methylation which may contribute to the AD pathology
(Fig. 1 (b)) [63]. In Down syndrome patients, increased
levels of plasma Aβ and a decreased methylation of three
CpGs which have been reported to predict aging in adults
are observed; these results indicate that Aβ contributes to
the observed accelerated aging in Down syndrome pa-
tients [64]. Endogenous peptides are thus able to regulate
gene expression and exert their effects by selectively in-
creasing or decreasing DNA methylation.
The effects of endogenous peptides are not limited to
DNA methylation but also include effects on histone
modifications. The human pro-islet peptide (HIP), a 14-
amino acid-containing peptide which is suggested as a
Table 1 An overview of the effects of peptides on different epigenetic systems
Epigenetic mechanism Peptide Effect Type Source Status Reference
DNA methylation Short peptides Inhibition Direct Endogenous/synthetic Pre-clinical [59–61]
Aβ Inhibition Indirect Endogenous Pre-clinical [62–64]
BCM7 Inhibition Indirect Milk Pre-clinical [65–67]
GM7 Inhibition Indirect Wheat Pre-clinical [66]
Histone methylation HIP Inhibition Indirect Endogenous Clinical [68]
EZH2 antagonists Inhibition Direct Synthetic Pre-clinical [69]
WHSC1 antagonist Inhibition Direct Synthetic Pre-clinical [70]
Histone demethylation LSD1 antagonists Inhibition Direct Synthetic Pre-clinical [71]
Histone acetylation Lunasin Inhibition Direct Soybean Clinical [72]
Histone deacetylation Romidepsin Inhibition Direct Bacterial Approved [73]
Burkholdacs Inhibition Direct Bacterial Pre-clinical [74]
Spiruchostatins Inhibition Direct Bacterial Pre-clinical [75]
Thailandepsin Inhibition Direct Bacterial Pre-clinical [76]
FR901375 Inhibition Direct Bacterial Pre-clinical [77]
Largazole Inhibition Direct Bacterial Pre-clinical [78]
Plitidepsin Inhibition Direct Tunica Clinical [79]
Chlamydocin Inhibition Direct Fungal Pre-clinical [80]
Trapoxins Inhibition Direct Bacterial Pre-clinical [81]
CHAP Inhibition Direct Synthetic Pre-clinical [82, 83]
Apicidin Inhibition Direct Bacterial Pre-clinical [84]
Microsporins Inhibition Direct Fungal Pre-clinical [85]
Azumamides Inhibition Direct Sponge Pre-clinical [86]
FR235222 Inhibition Direct Fungal Pre-clinical [87]
AS1387392 Inhibition Direct Fungal Pre-clinical [88]
miRNA LK-L1C/K6W/L8C miR-29b ↑ Direct Synthetic Pre-clinical [89]
LKKLLKLLKKWLKLKGX
LKKLLKLLKKLWKLKGX
miR-155 ↓ Direct Synthetic Pre-clinical [90]
L50 miR-21 ↓ Direct Synthetic Pre-clinical [91]
LncRNA BNP (Nesiritide) LSINCT5 ↑ Direct Endogenous Approved [92]
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therapeutic peptide for the treatment of diabetes, in-
creases β-cell mass, and improves glycemic control. This
peptide promotes differentiation of human fetus-derived
pancreatic progenitor cells by promoting expression of
different important pro-islet transcription factors through
phosphorylation and inhibition of the FOXO1 transcrip-
tion factor. This inhibition leads to a reduced menin bind-
ing to the promotor region of the pro-islet transcription
factors and a subsequent decreased recruitment of H3K9
methyltransferases (Fig. 1 (c)). Thus, the HIP peptide ex-
erts its effects by an indirect repressive effect on histone
methylation in the promotor region of pro-islet transcrip-
tion factors resulting in a promoted expression [68].
Peptides also affect the expression of ncRNAs. B-type-
natriuretic peptide (BNP), a cardiac hormone secreted
from the atrial and ventricular myocardium, promotes
myocardial cell apoptosis during myocardial ischemia-
reperfusion injury by upregulation of the lncRNA
LSINCT5. This lncRNA regulates myocardial cell apop-
tosis via activation of the caspase-1/IL-1β pathway caus-
ing chronic heart failure. Thus, elevated BNP levels can
result in chronic heart failure and is therefore an excellent
diagnostic marker [92, 94]. These effects could explain the
increased mortality risk after nesiritide treatment [95].
Nesiritide, a recombinant form of the peptide, is already
been approved by the FDA since 2001 for the symptom-
atic treatment of acute decompensated heart failure due
to its vasodilating activity. This product is not approved in
the European Union and Japan. In the years following ap-
proval, its benefits were being questioned, and in 2011, it
Fig. 1 Schematic overview of peptide effects on different epigenetic mechanisms. (a) Short peptides inhibit DNA methylation by blocking DNA
methyltransferase binding or initiation of strand separation. (b) BCM7, GM7, and Aβ suppress DNA methylation by inhibiting cysteine uptake and
lowering the SAM/SAH ratio in the cell. (c) HIP inhibits histone methylation indirectly by suppressing the FOXO1 transcription factor and
subsequent menin binding and histone methyltransferase recruitment. (d) Lunasin blocks H3 and H4 histone acetylations by preventing HAT
interaction. (e) Cyclic depsi- and tetrapeptides inhibit histone deacetylases by interaction with zinc atoms in the binding pocket of the enzyme. (f,
g) Synthetic peptide antagonists block the interaction sites of the HDM and HMT enzymes. (h) Synthetic peptides either promote or suppress
Dicer-mediated maturation of miRNA
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was demonstrated in a large-scale clinical trial (n = 7141)
that nesiritide shows no benefits over placebo-treated pa-
tients and it was concluded that this medicine could not
be generally recommended for routine use [96, 97]. Des-
pite this information, the product is still not withdrawn
from the US market.
Food-derived peptides
Trivedi et al. demonstrated that beta-casomorphin-7
(BCM7) and GM7, cryptic peptides released by hydrolytic di-
gestion of respectively casein and gliadin, decrease cysteine
uptake in neuronal and gastrointestinal cells via activation of
opioid receptors. This decrease is accompanied by increased
oxidation of intracellular glutathione and increased DNA
methylation at positions +65 to +80 of the gene transcription
start sites resulting in downregulation of several genes of the
transsulfuration pathway and methionine cycle [65, 66].
These results suggest that milk- and wheat-derived peptides
exert antioxidant effects important during postnatal develop-
ment by epigenetic mechanisms. BCM7 also promotes
neurogenesis of neuronal stem cells by decreasing global
DNA methylation (Fig. 1 (b)) [67].
Lunasin, a 43-amino acid soybean-derived polypeptide,
is able to inhibit core histone acetylation of H3 and H4
and has been shown to exhibit marked anti-cancer activ-
ities (Fig. 1 (d)) [72, 98]. At its carboxyl-terminal end, the
peptide contains 8 negatively charged Asp residues which
act as the inhibitor of the positively charged H3 and H4
acetylations. This sequence is immediately preceded by an
Arg-Gly-Asp (RGD) motif which is responsible for attach-
ment to the extracellular matrix and facilitating cell pene-
tration of the peptide, and a 9-amino acid-long α-helical
structure which guides and binds lunasin to the core his-
tone proteins [99]. Recently, it has been found that this
peptide also exerts beneficial effects in neurodegenerative
diseases such as AD and ALS [100, 101].
Next to modulating DNA methylation and histone
modifications, food-derived peptides can also exert regu-
latory effects on ncRNA transcription. A peptide hydrol-
ysate extract, i.e., a peptide mixture derived from the
soft-shelled turtle (a functional food in Chinese trad-
itional medicine), modulates the expression of 101 dif-
ferent miRNAs in human gastric cancer cells. Many of
the upregulated miRNAs have tumor suppressive actions
(they target oncogenes), making the peptide a potential
therapeutic anti-cancer peptide [102].
The effects of food-derived peptides on epigenetics and
their possible use in the treatment of diseases make these
products subject of the discussion whether these should
be considered as functional foods or as medicinal prod-
ucts (so-called borderline products). A medicinal product
is seen as a product presented as having properties for
treating or preventing disease in human beings or having
restoring, correcting, or modifying physiological functions,
while no single legislative definition currently exists for
functional foods. Generally, it is stated that a functional
food contains next to its nutritional impact also beneficial
health effects [103]. In the case of “borderline products,”
the European Court of Justice (ECJ) decisions are con-
structive: e.g., in the Hecht-Pharma case (Case C-140/07),
the ECJ decided that a product composed of fermented
red rice, which contains monacolin (a cholesterol-
lowering molecule), should be considered as a food sup-
plement, contrary to the German administrative author-
ities which classified it as a medicinal product. This
decision was based on the fact that all the characteristics
of a product are relevant for its classification. So whether
a product with epigenetic bioactive peptides is classified as
a medicinal product or as a food product depends on
characteristics such as composition, pharmacological ef-
fect, manner of use, dosage, distribution, and familiarity of
the risks to the consumers. Based on this ECJ ruling,
pharmaceutical law only applies to products sold for treat-
ment, cure, or prevention of human diseases and to prod-
ucts which, by composition, are scientifically proven to
modify physiological functions [104].
Environmental peptides
These peptides can be found in the environment and are
mainly produced by microbial species. Romidepsin, a fer-
mentation product of Chromobacterium violaceum, is the
first FDA-approved peptide-based drug with epigenetic ef-
fects. It is a broad-spectrum HDAC inhibitor (HDACi)
but is mainly active against class I HDACs. Within the
cell, the disulfide bond of the peptide is reduced releasing
thiol in this process. This thiol interacts with zinc atoms
in the binding pocket of zinc-dependent HDAC, thereby
inhibiting its activity (Fig. 1 (e)) [73]. Other depsipeptides,
such as spiruchostatins (A, B and C), FR901375, largazole,
plitidepsin, burkholdacs (A and B), and thailandepsin B,
belong to the same group as romidepsin and have similar
working mechanisms (Fig. 2) [74–76, 105]. The spiruchos-
tatins, burkholdacs, and thailandepsin B all originate from
the bacterium Burkholderia thailandensis. Burkholdacs com-
pounds differ from the spiruchostatins by the substitution of
methionine with alanine [74]. FR901375 and largazole are
structurally closely related to romidepsin and are respectively
fermentation products of Pseudomonas chlororaphis and the
marine cyanobacterium Symploca sp. [77, 78]. Plitidepsin
(Aplidin®) is a cyclic depsipeptide originating from the mar-
ine tunica Aplidium albicans. It has pleiotropic effects on
cancer cells by binding to the eEF1A2 protein, which results
in cell-cycle arrest, growth inhibition, and induction of apop-
tosis by different pathways and is also considered as a HDAC
inhibitor [79, 106]. Numerous clinical trials have been con-
ducted on the use of this peptide alone or in combination
with other anticancer agents in the treatment of various can-
cer types. The most promising effect was the combined
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treatment in relapsed/refractory multiple myeloma together
with dexamethasone [79, 107, 108]. However, the European
Medicines Agency (EMA) refused market authorization of
this product in 2018 based on the modest improvement in
overall survival and the more frequent severe side effects that
occurred. The EMA concluded that the benefits did not out-
weigh its risks for the proposed broad indications [109].
A second class of peptide HDACi are the cyclic tetrapep-
tides. Belonging to this group are chlamydocin, apicidin,
FR235222, microsporins (A and B), azumamides (A-E), and
the trapoxins (Fig. 3) [110]. Chlamydocin, a fungal metabolite
with a strong HDAC inhibitory potency, induces hyperacety-
lation of histones H3 and H4, resulting in G2/M cell cycle
arrest and induction of apoptosis by activating caspase-3. In
addition, it downregulates survivin, an inhibitor of apoptosis
which is selectively expressed in tumors [80]. Over the years,
numerous chlamydocin analogues have been found or devel-
oped [110–113]. Trapoxin A is isolated from the fungal para-
site Helicoma ambiens; just like chlamydocin, it contains a 6-
oxo-7,8-epoxyoctyl side chain which serves as the Zn2+-co-
ordinating group and its ketone carbonyl group is isosteric
with the scissile carbonyl of the HDAC substrate acetyl-L-
lysine, acting like an irreversible class I HDACi [81]. The tra-
poxin A and trichostatin A molecules are often combined
replacing the epoxyketone structure of trapoxin A with a
hydroxamic acid from trichostatin A resulting in a hybrid
cyclic hydroxamic-acid-containing peptide (CHAP). This
way, target enzyme specificity is affected which can lead to
the development of isoform-specific HDAC inhibitors [82,
83]. Apicidin is structurally analogous to trapoxin A; it lacks
the epoxyketon functional group but also shows HDAC in-
hibitory activity and has similar effects as chlamydocin [81,
84]. Microsporins A and B are isolated from the marine-
derived fungus Microsporum gypseum and are together with
azumamide A-E, derived from the sponge Mycale izuensis,
the first marine-isolated cyclic tetrapeptides with inhibitory ac-
tivities against HDAC [85, 86]. FR235222 and its analogue
AS1387392 are two fungal metabolites, isolated from Acremo-
nium species, that show immunosuppressive activities. These
two cyclic tetrapeptides are able to inhibit T cell proliferation
and lymphokine production by inhibiting histone deacetylase
[87, 88]. The structure of these natural occurring cyclic pep-
tides has been used several times to design more selective and
potent peptide-based HDAC inhibitors [114, 115].
Synthetic peptides
Lysine-specific demethylase 1 (LSD1) is a chromatin-
remodeling enzyme which removes methyl groups from
Fig. 2 Structures of acyldepsipeptides
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lysine at position 4 of histone H3. This enzyme plays an
important role in cancer as over-expression results in silen-
cing of tumor-suppressing genes, and it is thus regarded as
an attractive target for therapeutic interventions. Different
peptide-based inhibitors have already been developed; these
peptides are analogues of the histone H3 lysine 4 substrate
region of LSD1 and act as antagonists (Fig. 1 (f)). However,
neither one is currently yet under human clinical investiga-
tion [71]. The structures of these peptide antagonists are
modified to optimize the potency of these inhibitors. Forneris
et al. created a peptide where lysine at position 4 is replaced
by methionine, which resulted in an improvement in Ki from
1.8 to 0.04 μM [116]. Replacement of alanine at position 1
with a serine residue also resulted unexpectedly in a potent
inhibitor [117]. Next to substituting amino acids, lysine can
also be modified by more complex moieties such as trans-2-
phenylcyclopropylamine or by cyclization [71, 118]. These
modifications resulted in the development of inhibitors with
IC50 values in the nanomolar range [119]. Another approach
is to design peptide substrates which block the interaction of
LSD1 with its target transcription factors, resulting in a more
selective activation of LSD1 target genes [120].
EZH2 is a histone methyltransferase that catalyzes di-
and trimethylation of lysine at position 27 of histone H3
and is linked to gene repression. Overexpression of this
enzyme has been correlated to various cancer types due
to epigenetic silencing of important tumor suppressor
genes [121]. Smadbeck et al. used an in silico approach
to design inhibitory peptides of EZH2. Using an integer
linear optimization model, 17 sequences were predicted
to have significantly higher binding affinities to EZH2
than the native H3-derived peptide (Fig. 1 (g)). From
these 17 peptides, 10 peptides were selected for experimental
validation using a HMT enzymatic assay, which assessed the
EZH2-dependent transfer of tritiated methyl-groups from
the SAM donor to reconstituted oligonucleosomes. This ap-
proach resulted in peptide inhibitors with IC50 values in the
micromolar range [69]. However, this observed potency is
significantly lower than those of previously discovered small
molecule inhibitors of EZH2 [122]. Morrison et al. developed
different HMT inhibiting norleucine containing peptides
with IC50 values in the micromolar range. These peptides in-
hibit HMT from the NSD family and are derived from the
histone H4 sequence [70].
Next to affecting DNA- and histone modifications, syn-
thetic peptides can also interact with the hairpin structure of
miRNAs, affecting their activity such as changing the effi-
ciency of miRNA maturation. Inhibiting miRNA maturation
results in suppressed miRNA formation and successive up-
regulation of the miRNA target genes. However, stabilizing
miRNA maturation can result in an enhanced downregula-
tion of the miRNA’s targets. This strategy can be used to tar-
get suppressors of p53, the main tumor suppressor protein,
in new approaches for treating cancer. LK-L1C/K6W/L8C is
Fig. 3 Structures of cyclic tetrapeptides
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an amphiphilic peptide that binds to the terminal loop region
of pre-miR29b which matures to miR29b and induces apop-
tosis of cancer cells through p53 stabilization. Binding of this
peptide to pre-miR29b improves the complexation with
Dicer, the enzyme responsible for miRNA maturation, and
enhances miR29b expression. This peptide is thus able to in-
crease apoptosis induction in cancer cells by upregulation of
miR29b and p53 [89]. MiR-155 is one of the most potent
miRNAs that suppress apoptosis in human cancer cells and
is overexpressed in numerous types of cancer. Using peptide
microarrays, Pai et al. found two peptides which are able to
inhibit Dicer-mediated miRNA-155 maturation, hereby up-
regulating the target genes of miRNA-155 and promoting
apoptosis by caspase-dependent pathways. These peptide in-
hibitors bind to the apical stem-loop region of pre-miRNA,
hereby blocking the interaction site of Dicer and suppressing
the Dicer-mediated processing and are thus potential new
therapeutics in treating various types of cancer [90]. Short-
ridge et al. discovered a macrocylic peptide which is able to
bind pre-miR21 also hampering Dicer-mediated maturation
to miR21, a miRNA overexpressed in many cancers, by
screening an existing peptide library of 54 peptides [91]. Pre-
miRNA interacting peptides that inhibit maturation can also
be discovered using the phage display technology [123, 124].
These studies indicate that peptides can either promote or
inhibit the Dicer-mediated maturation of pre-miRNA to ma-
ture miRNA, hereby upregulating important tumor suppres-
sor genes or downregulating oncogenes which are overly
expressed in cancer (Fig. 1 (h)). Targeting these epigenetic
mechanisms, peptides or peptide analogues used as antago-
nists can have great potential to be used as epigenetic drugs
for treating not only cancer, but a wide variety of diseases.
Effects of epigenetics on peptide expression
Peptides can thus have an effect on multiple aspects of epi-
genetic regulation. However, endogenous peptide expression
is also regulated by epigenetic mechanisms. For example,
during withdrawal of both tobacco smoking and alcohol
consumption, expression of natriuretic peptides and vaso-
pressin are regulated by changing DNA methylation patterns
in the promotor regions of the peptides [125–128]. HDACs
are able to downregulate the expression of cationic anti-
microbial peptides; therefore, treatment with HDACi can be
an alternative approach to combat bacterial infections and
tackle the problem of emerging antibiotic resistance by up-
regulating the expression of these antimicrobial peptides
[129]. Also in cancer tissue, epigenetic mechanisms are re-
sponsible for the expression of cancer-specific peptides such
as the trefoil factor family, consisting of peptides with pivotal
roles in oncogenic transformation [130, 131]. Recently, cryp-
tic long terminal repeat (LTR) transcription of endogenous
retroviruses (ERV) has been observed as a novel class of
treatment-induced non-annotated out of frame dsRNA tran-
scripts (TINATs) upon epigenetic therapy with DNMT and
HDAC inhibitors [132]. The resulting transcripts frequently
encode truncated or chimeric open reading frames translated
into products with predicted abnormal or immunogenic
functions. While these out-of-frame transcripts are likely
subjected to nonsense-mediated decay (NMD), chimeric
peptide sequences encoded in TINAT fusion transcripts are
potentially immunogenic based on their foreign sequence
and their capability of being presented on MHC class I mol-
ecules for recognition by cytolytic T cells [132–134].
Therapeutic implications
FDA-approved epigenetic drugs
Since the strong involvement of epigenetic mechanisms in
different diseases, molecules which inhibit or enhance these
epigenetic modifications are being developed [51]. Prachaya-
sittikul et al. have nicely summarized the currently available
DNA methyltransferase inhibitors (DNMTi), histone methyl-
transferase- and demethylase inhibitors (HMTi and HDMi),
histone acetyltransferase and deacetylase inhibitors (HATi
and HDACi), sirtuin inhibitors (SIRTi), and bromodomain
inhibitors (BRDi) [11]. Epigenetic drugs which are under in-
vestigation are also collected in a database named the “Hu-
man epigenetic drug database (HEDD)” [106]. To date, 11
drugs with epigenetic effects are approved by the FDA of
which 7 are targeting different kinds of cancer by upregulat-
ing tumor suppressor genes (Table 2) [11, 135]. These drugs
all target hematopoietic cancers as these cancer types are
more sensitive to this type of drugs. However, combination
treatment of solid tumors with epigenetic drugs and DNA
damaging chemotherapeutics or immunotherapy can act in
a synergistic way resulting in a more efficient treatment
[135–137]. In 2009, the first peptide-derived epigenetic drug
(romidepsin) was approved for the treatment of cutaneous T
cell lymphomas (CTCL), and in 2011 for peripheral T cell
lymphomas (PTCL) [73]. In addition, it has a potential use in
other kinds of cancer, lung fibrosis, and Epstein-Barr infec-
tions [138–140]. Currently, it is the only FDA-approved pep-
tide medicine with epigenetic effects together with nesiritide.
However, nesiritide was, just like other traditional drugs (val-
proic acid, procainamide, hydralazine), not approved for its
epigenetic effects but for their non-epigenetic medicinal ef-
fects. Their epigenetic properties were only discovered more
recently, making them excellent candidates for drug repur-
posing [141–143]. Despite the FDA approval status of both
romidepsin and nesiritide, the peptides are not approved in
the European Union by the EMA [144, 145]. The EMA re-
fused market authorization of romidepsin based on the ab-
sence of a treatment control group in the main clinical trial
[146]. Furthermore, they did not authorize nesiritide as they
are awaiting more long-term data on (renal) side effects and
mortality of this product [145]. Recent evidence shows that
valproic acid and procainamide can be efficacious in the
treatment of cancer, whereas the first clinical trials using val-
proic acid as a combination therapy in advanced sarcomas
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have already started [142, 147]. Hydralazine has the poten-
tial to be used against chronic heart and kidney failure
[143]. Pargyline, a monoamine oxidase inhibitor which
was brought on the market in the 1960s as an antihyper-
tensive drug, shows some sequence and structural similar-
ity to demethylases from the LSD1/KDM1 family, and
indeed, this compound is able to inhibit the histone
demethylase KDM1A [148]. However, in 2007, this com-
pound was discontinued and is no longer on the market.
In 2014, an orally active HDACi (Chidamide) was ap-
proved in China for the treatment of recurrent and refrac-
tory peripheral T cell lymphoma; however, it is still not
approved worldwide [149]. Several other molecules are
currently in different phases of clinical trial [51].
Pharmaceutical peptide development for epigenetic
therapy
Peptides represent a unique class of pharmaceutical com-
pounds, residing in the gray area between small molecules
and proteins yet therapeutically and biochemically differ-
ent from both. The first use of peptides as therapeutics
started in the 1920s, where insulin was used as a replace-
ment therapy for treating diabetes. Peptides show several
advantages over small molecules: they are highly selective
and potent, are well tolerated (reduced toxicity), and have
a predictable metabolization. In addition, peptide thera-
peutics generally have lower attrition rates during clinical
development and a shorter time to market approval [96].
The peptide therapeutic market is an ever increasing market
with an estimated annual growth rate of 9% between 2016
and 2024. Estimations indicate that this market will reach 50
billion dollars by 2024, thus becoming more and more im-
portant in the pharmacological landscape [150]. Techniques
such as phage display enable us to screen enormous amounts
of peptide ligands which fastens drug discovery [151]. How-
ever, peptides also have notable drawbacks such as a low
plasma stability due to rapid degradation by proteases and a
low oral bioavailability [96, 152]. To counteract these limita-
tions, different strategies can be applied to improve the ad-
sorption, distribution, metabolization, and elimination
(ADME) properties of peptides such as cyclization, conjuga-
tion to macromolecules, replacing L-amino acids with D-iso-
forms and N-methylation of the peptide bond [153, 154]. To
date, over 60 peptide drugs are approved in one of the major
markets (USA, EU, and Japan) and over 150 are under devel-
opment and have entered human clinical trials. A recent
overview of all approved (and withdrawn) peptide drugs is
given by Lau et al. [96]. Romidepsin is not included in the list
as it is a depsipeptide and surprisingly not considered as a
peptide drug. Depsipeptides are peptides in which one or
more amide bindings are replaced with an esther binding.
Nesiritide, the recombinant form of BNP, is approved for the
treatment of heart failure. However, its routine use for treat-
ment of chronic heart failure is controversial [97]. Several
clinical trials are ongoing to use this peptide in other indica-
tions such as diabetes and pulmonary hypertension [155].
No other peptides that target epigenetic mechanisms are yet
approved in one of the major markets, and only three others
have been or are under clinical development (i.e., lunasin, pli-
tidepsin, and HIP). Recently, a clinical trial using lunasin in
the treatment of ALS has been completed. Participants who
were receiving lunasin were able to perform slightly better
on different functional activities such as swallowing and
walking [156, 157]. It was found that H3K9K14ac2 and
H4K5K8K12K16 acetylation in blood cells was lower in
treated patients compared to untreated controls, demonstrat-
ing the inhibitory histone acetylation effects of lunasin. An-
other clinical trial compared the effect of lunasin with a
dietary supplement (Reliv NOW) on cardio-metabolic risk
factors, but no results were reported [158]. To date, a dietary
supplement containing a high lunasin concentration is
already on the market (LunaRich XTM, Reliv) and is freely ac-
cessible online. Several health claims are being made, and
the product is marketed as “the first epigenetic superfood.”
Plitidepsin (Aplidin®), alone or in combination with
other treatments, was included in 11 different clinical tri-
als for treating different types of cancer. As already dis-
cussed, this peptide was refused market approval by the
EMA for the treatment of relapsed/refractory multiple
myeloma as its benefits did not outweigh its risks [109].
A first phase 1 clinical trial using HIP for the treat-
ment of diabetes mellitus has been conducted of which
no results are available yet [159]. All the other discussed
peptides in this review are currently not under clinical
development, but are/were investigated in fundamental
and/or pre-clinical research.
So, despite the highly potent and promising effects of
peptides in modulating epigenetics for the treatment of
for example cancer, this does not yet translate in a signifi-
cant number of therapeutic products which are currently
Table 2 FDA-approved drugs with epigenetic effects
Drugs Classification Indicated disease Approved year
Procainamide DNMTi Cardiac arrhythmia 1950
Hydralazine DNMTi Hypertension 1953
Valproic acid HDACi Epilepsy/seizures 1978
Nesiritide LncRNA upregulator Heart failure 2001
Azacitidine DNMTi MDS 2004
Vorinostat HDACi CTCL 2006
Decitabine DNMTi MDS 2006
Romidepsin HDACi CTCL/PTCL 2009/2011
Ruxolitinib JAK1/2 inhibitor Myelofibrosis 2011
Belinostat HDACi PTCL 2015
Panobinostat HDACi MM 2015
MDS myelodysplastic syndrome, CTCL cutaneous T cell lymphoma, PTCL
peripheral T cell lymphoma, MM multiple myeloma
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being developed or are on the market. This can be ex-
plained by the limitations of peptide drugs such as the low
oral availability, the very low plasma stability, and high ex-
cretion by the kidneys. Improving the pharmacokinetic
properties of peptides by increasing the metabolic stability
(i.e., protection against degradation by proteases and pep-
tidases), extending the biological activity (e.g., increased
protein binding), increasing membrane association, and
changing the tissue distribution and/or excretion rate (e.g.,
through self-aggregation) can overcome these problems.
The pharmacokinetic properties of a peptide are optimized
using chemical modifications such as changing L-amino acids
with D-amino acids, cyclization, conjugation (e.g., acylation,
pegylation, glycosylation), amide bond protection (e.g., N-
methyl groups), and incorporation of altered or unnatural
amino acids (e.g., tert-butyl group on serin).
An alternative approach for targeting ncRNAs (or
mRNA) is the use of peptide nucleic acids (PNAs). These
are DNA analogues in which the sugar-phosphate back-
bone is replaced by N-(2-aminoethyl)glycine units [160].
The main advantage of these PNAs is that they are resist-
ant against both nucleases and proteases and can have a
variety of functions such as inhibiting miRNA maturation
[161], lncRNA-protein interaction [162], and miRNA-
mediated mRNA degradation [163]. While these PNAs
are not peptides sensu stricto, they can be linked to cell-
penetrating peptides to deliver these active PNAs in the
cell where they exert their functions [161, 162, 164].
Drug repurposing
Drug repurposing or repositioning is the application of
known, approved, drugs to new indications which clearly of-
fers cost and time benefits. Different developmental risks are
reduced because repositioning candidates have already been
through several stages of clinical development and often
long-term safety profiles and pharmacokinetic profiles are
known [165]. Currently, a lot of research is going on to in-
vestigate the epigenetic effects of already FDA-approved
drugs and their possible applications in for example cancer
and neurodegenerative disorders. By screening an FDA-
approved library of 1206 drugs in combination with DNMTi
or HDACi, Raynal et al. discovered that 4% (n= 45) of the
investigated drugs enhanced DNMTi or HDACi activity in a
human colon cancer cell line [166]. Hydralazine-valproate is
a drug combination being repositioned to an oral DNMT
and HDAC inhibitor and is currently in phase II trials for
breast cancer and refractory solid tumors and in phase III tri-
als for the treatment of advanced cervical cancer. This com-
bination drug has already been approved in Mexico since
2009 for the treatment of advanced cervical cancer [167].
Chatterjee et al. propose 14 compounds for repositioning in
the treatment of Alzheimer’s disease as these drugs share the
same epigenetic targets which are involved in AD develop-
ment [168].
Several approved peptide drugs are already being repo-
sitioned to other indications. For example, lisinopril, a
synthetic tripeptide derivative approved for treatment of
hypertension and heart failure, binds strongly to neur-
aminidase and has antiviral activity against influenza A
[169]. Glatiramer, approved for the treatment of multiple
sclerosis, shows promising effects in Huntington’s disease
and as an antibiotic [170, 171] and liraglutide against obesity,
non-alcoholic fatty liver disease, and depression [172, 173].
Other examples of approved peptide drugs with possible
therapeutic effects in other indications exist [174–177].
However, none of the currently approved peptide drugs are
under consideration for repositioning due to the discovery of
epigenetic effects as none of these peptide drugs, which are
under clinical trial for other indications they were initially ap-
proved for, have demonstrated epigenetic effects. For the
moment, there is an intriguing knowledge gap concerning
the possible epigenetic effects of the approved peptide drugs
on the market. Seen the potential of peptides to modulate
the different epigenetic mechanisms, it is not unlikely that
some of the approved peptide drugs exert modulatory epi-
genetic effects and can have the potential to be used in
diseases with a strong epigenetic basis such as cancer or
AD [178, 179].
Conclusion
Today, epigenetic research has attracted pharmaceutical
interest. Research is being performed to dissect epigenetic
mechanisms in a variety of diseases and to develop small
molecule epigenetic drugs. Surprisingly, the therapeutic po-
tential of peptides with epigenetic properties remains under-
explored. Despite the many therapeutic advantages of
peptides over small molecules, only two (depsi-)peptide
drugs with epigenetic modulating properties are currently
approved by the FDA and on the market. Drug repurposing
can help accelerating marketing approval of already existing
peptide drugs for other indications. Currently, none of the
existing peptide drugs have been investigated for potential
epigenetic effects. Focusing on these potential effects can ac-
celerate therapeutic development of new, highly potent pep-
tides for the treatment of diseases with a strong epigenetic
basis such as cancer and/or Alzheimer’s disease.
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